These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

70 related items for PubMed ID: 18565596

  • 1. Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers.
    Hilpert J, Beekman JM, Schwenke S, Kowal K, Bauer D, Lampe J, Sandbrink R, Heubach JF, Stürzebecher S, Reischl J.
    J Neuroimmunol; 2008 Aug 13; 199(1-2):115-25. PubMed ID: 18565596
    [Abstract] [Full Text] [Related]

  • 2. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
    Bitsch A, Bahner D, Wachter C, Elitok E, Bogumil T, Dressel A, Polak T, Tumani H, Weber F, Poser S, Kitze B.
    Acta Neurol Scand; 2004 Dec 13; 110(6):386-92. PubMed ID: 15527451
    [Abstract] [Full Text] [Related]

  • 3. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis.
    Serrano-Fernández P, Möller S, Goertsches R, Fiedler H, Koczan D, Thiesen HJ, Zettl UK.
    Autoimmunity; 2010 Mar 13; 43(2):172-8. PubMed ID: 19883335
    [Abstract] [Full Text] [Related]

  • 4. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 13; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 5. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B, Bhasi K, Badgett D, Tamaño-Blanco M, Minhas M, Feichter J, Patrick K, Munschauer F, Bakshi R, Ramanathan M.
    J Neuroimmunol; 2008 Dec 15; 205(1-2):113-25. PubMed ID: 18950872
    [Abstract] [Full Text] [Related]

  • 6. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients.
    Satoh J, Nakanishi M, Koike F, Onoue H, Aranami T, Yamamoto T, Kawai M, Kikuchi S, Nomura K, Yokoyama K, Ota K, Saito T, Ohta M, Miyake S, Kanda T, Fukazawa T, Yamamura T.
    J Neuroimmunol; 2006 May 15; 174(1-2):108-18. PubMed ID: 16564577
    [Abstract] [Full Text] [Related]

  • 7. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K, O'Leary C, Coret Ferrer F, Klímová E, Procházková L, Bugge J, BRIGHT Study Group.
    Mult Scler; 2007 Nov 15; 13(9):1153-60. PubMed ID: 17967843
    [Abstract] [Full Text] [Related]

  • 8. Novel interferon-beta-induced gene expression in peripheral blood cells.
    Rani MR, Shrock J, Appachi S, Rudick RA, Williams BR, Ransohoff RM.
    J Leukoc Biol; 2007 Nov 15; 82(5):1353-60. PubMed ID: 17709400
    [Abstract] [Full Text] [Related]

  • 9. Gene expression analysis of interferon-beta treatment in multiple sclerosis.
    Sellebjerg F, Datta P, Larsen J, Rieneck K, Alsing I, Oturai A, Svejgaard A, Soelberg Sørensen P, Ryder LP.
    Mult Scler; 2008 Jun 15; 14(5):615-21. PubMed ID: 18408020
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy.
    Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M, Yoshida J.
    J Gene Med; 2008 Apr 15; 10(4):329-39. PubMed ID: 18220319
    [Abstract] [Full Text] [Related]

  • 12. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D, Sellebjerg F, Sorensen PS.
    Neurology; 2009 Aug 04; 73(5):372-7. PubMed ID: 19652141
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
    Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM.
    Clin Cancer Res; 2008 Jul 15; 14(14):4500-10. PubMed ID: 18628465
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y, Kawachi Y, Furuta J, Otsuka F.
    Eur J Dermatol; 2008 Jul 15; 18(5):579-82. PubMed ID: 18693165
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
    Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E.
    Mult Scler; 2009 Jan 09; 15(1):50-8. PubMed ID: 18922831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.